Cresco Labs is the latest marijuana multistate operator to scoop up assets from flailing competitor PharmaCann, this time in medical marijuana-only Pennsylvania.
Chicago-based Cresco acquired nine Pennsylvania medical marijuana dispensaries from PharmaCann in a “cash-free, debt-free” $50 million transaction, according to a Wednesday announcement.
The $50 million purchase price, paid through a combination of cash and a seller note, makes Cresco the top medical marijuana retailer and wholesaler in MMJ-only Pennsylvania, the company said. Cresco did not disclose the value or terms of the seller note.
“Pennsylvania is one of our core markets, where scale and vertical integration create durable competitive advantages,” Cresco Labs CEO Charlie Bachtell said. “Pairing more retail doors with our scaled cultivation and leading wholesale business reinforces our position as the consolidator of choice in the markets that matter most.”
The acquisition comes amid a broader wave of consolidation in the U.S. cannabis industry, as well-capitalized operators increasingly turn to M&A to expand their footprints and acquire assets from financially strained competitors.
Why did Cresco target Pennsylvania for cannabis M&A?
Chicago-based MSO PharmaCann has been selling off assets after closing at least three cultivation facilities in recent months, including its cultivation and manufacturing facility in Olyphant, Pennsylvania, where 60 employees were laid off.
Pennsylvania is the second-largest medical marijuana market in the country behind Florida, generating more than $1.8 billion in sales last year, according to the Pennsylvania Department of Health.
However, adult-use cannabis legalization proposals are stalled in the state legislature despite repeated demands from Gov. Josh Shapiro – and a state budget deficit.
That scale, combined with Pennsylvania’s limited number of medical marijuana dispensary permits, makes existing dispensaries particularly valuable.
Cresco expects the deal to be immediately accretive to revenue, margins and cash flow, a claim that reflects its ability to route its branded products – Cresco, High Supply, FloraCal and others – through newly acquired dispensaries.
Following Wednesday’s announcement of the $50 million acquisition, Cresco stock closed slightly higher at $0.7840 per share before falling to $0.7410 by market close Thursday.
What’s driving cannabis M&A ?
The purchase fits a broader pattern among multistate operators, who have spent the past several months buying retail and cultivation assets in mature, limited-license markets rather than chasing new state expansions.
Exclusive industry data and analysis to help you make informed business decisions and avoid costly missteps. All the facts, none of the hype. What you will get: Subscribe to the MJBiz Factbook
PharmaCann’s recent deals include the sale of its New York medical cannabis license and related assets to Grown Rogue and 17 Colorado LivWell dispensaries to Vireo Growth. Cresco, meanwhile, has pursued selective growth in key markets, including a bid to enter Texas’ expanding medical cannabis program earlier this year, though state regulators later revoked its conditional permit.
Lawmakers have debated adult-use legalization for several sessions without passing a bill, leaving the medical program as the only legal channel.
